Biological data

PreclinicalBiologic

UUniversity Hospital, Bordeaux

Biological data is one of 180 biologic programs targeting Arrhythmia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

179

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Fabry DiseaseActive, not recruiting

COVID-19Active, not recruiting

Myelodysplastic SyndromesActive, not recruiting

EEGRecruiting

ConcentrationCompleted

ArrhythmiaPreclinical

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Fabry DiseasePreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Myelodysplastic SyndromesPreclinical

Active, not recruiting

EEGPreclinical

Recruiting

ConcentrationPreclinical

Completed

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

86 2

Avastin

Oleclumab

7 4

ABP 234

Amgen

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Myelodysplastic Syndromes

NCT05924074

Q2 2041

Not yet recruiting

Non-Small Cell Lung Cancer

NCT07470476

Clinical

Trials by Indication[1]

COVID-193 trials

MYocardial DOmmages Related to COVID-19

Completed·—··NCT04498065·273 enrolled

EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

Unknown status·—··NCT04498091·35 enrolled

Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis

Completed·—··NCT04380987·1,366 enrolled

Concentration1 trial

Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index

Completed·UUniversity Hospital, Bordeaux·N/A·NCT01223157·24 enrolled

Arrhythmia1 trial

Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19

Completed·UUniversity Hospital, Bordeaux··NCT04937621·196 enrolled

Tumors1 trial

Microbiotic Analysis in Digestive Endocrine Tumors

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT04198402·50 enrolled

Myelodysplastic Syndromes1 trial

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05924074·80 enrolled

4 more indications

Inflammatory Bowel Disease1 trial

Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel Disease

Completed·IImagine Institute··NCT02909244·51 enrolled

Fabry Disease1 trial

Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes.

Unknown status·UUniversity Hospital, Bordeaux··NCT03123523·55 enrolled

Non-Small Cell Lung Cancer1 trial

Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease

Not yet recruiting·UUniversity Hospital, Bordeaux··NCT07470476·150 enrolled

EEG1 trial

EEG Microstates Across At-Risk Mental States

Recruiting·—·N/A·NCT06045897·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Biological data. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological data compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological data. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Bordeaux

Biological data

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2041

Trials by Indication[1]

COVID-193 trials

Concentration1 trial

Arrhythmia1 trial

Tumors1 trial

Myelodysplastic Syndromes1 trial

Inflammatory Bowel Disease1 trial

Fabry Disease1 trial

Non-Small Cell Lung Cancer1 trial

EEG1 trial

References

Drug Info

Quick Facts

Related News